In Segment C, individuals will get ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Participants will receive treatment until eventually sickness progression or the contributors are unable to tolerate the study drugs. Achievable new strategies for that analysis and treatment of AML. (A) The identification https://brd4-targetedtherapyabbv-35689.ampedpages.com/a-simple-key-for-abbv-744-brd4-inhibition-in-cancer-cell-lines-unveiled-59220148